ClinicalTrials.gg
RecruitingNCT07065734NEWERUpdated Jul 15, 2025

NEgative prEssure Wound Therapy in Renal Transplant

A Phase 4 interventional study of NWPT group in Transplant Complication, Renal Transplant and Wound Complication, sponsored by Centro Hospitalar De São João, E.P.E.. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-15.

Sponsored by Centro Hospitalar De São João, E.P.E. · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 5 months after the study started (first participant enrolled Jan 2023, registered Jun 2025).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective study involving patients undergoing open renal transplant. Renal transplant recipients were randomly divided into two groups: the NPWT group, which received NPWT, and the Standard group, which received standard wound dressings.

Read the detailed description

This is a prospective study involving patients undergoing open renal transplant between January 2023 and August 2024. Pediatric patients, those requiring surgical reinterventions within the first 3 postoperative months, and patients allergic to NPWT components were excluded from the study. Renal transplant recipients were randomly divided into two groups: the NPWT group, which received NPWT, and the Standard group, which received standard wound dressings. NPWT (PICO by Smith \& Nephew) was applied intraoperatively at 80 mmHg and maintained for 7 days. Wound evaluations were performed at 7, 14, 30, and 90 days post-operatively. If dehiscence was present, it was classified as either deep or superficial based on the involvement of the aponeurosis. Patients were assessed for wound infection using the ASEPSIS score, pain with a visual analogue scale, and quality of life using the EQ-5D questionnaire. Scar healing was also evaluated at 30 and 90 days post-operatively with the POSAS score

02

Conditions studied

  • Transplant Complication
  • Renal Transplant
  • Wound Complication

Keywords

  • transplant complication
  • renal transplant
  • wound complication
03

In context

Lead sponsor

Centro Hospitalar De São João, E.P.E. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients submitted to kidney transplant

Exclusion criteria

Exclusion Criteria:

  • Pediatric patients, those requiring surgical reinterventions within the first 90 days postoperative, patients allergic to NPWT components, orthotopic transplant
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    NPWT group

    Patients who received negative pressure wound therapy

    Device: NWPT group

  • No intervention
    Standard group

    Patients who received standard dressing

Interventions

  • DeviceNWPT group

    Patients submitted to negative pressure wound therapy

06

What researchers measure

Primary outcomes

  1. Wound dehiscence

    Wound dehiscence - superficial or deep

    Time frame: First 90 days after surgery

Secondary outcomes

  1. Wound infection

    ASEPSIS score - (Additional treatment, Serous discharge, Erythema, Purulen exudates, Separation of deep tissues, Isolation of bacteria, Stay in hospital score); 0-10 points; higher score = worse outcome

    Time frame: First 90 days after surgery

  2. Pain associated with incision

    Visual analogue scale; score 0-10; higher score=worse outcome

    Time frame: First 90 days after surgery

  3. Quality of life associated with incision

    EQ-5D questionnaire (The 5-level quality of life version 5); score 0 -100 ; highest score=better outcome

    Time frame: First 90 days after surgery

  4. Scar healing

    POSAS score (The Patient and Observer Scar Assessment Scale); score 1-10; highest score=worse outcome

    Time frame: First 90 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — IPD will be shared upon reasonable request after consideration from local Ethics Comission

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for May 2026, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 15, 2025
StartActual
Jan 1, 2023
Primary completionEst.
May 31, 2026
CompletionEst.
Jun 30, 2026
Last update
Jul 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07065734
Lead sponsor
Centro Hospitalar De São João, E.P.E.
Responsible party
Alberto Costa Silva (Principal Investigator, Centro Hospitalar De São João, E.P.E.) — Principal investigator
First posted
Jul 15, 2025
Start date
Jan 1, 2023
Primary completion
May 31, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jul 15, 2025

Study contacts

Alberto Silva, MD
Contact
u016845@chsj.min-saude.pt
+351225512100
João Alturas Silva, PhD
study director · São João University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion